PDCD1 and cancer: Monoclonal antibodies against PD-1 (nivolumab and pembrolizumab), PD-L1 (atezolizumab), and CTLA-4 (ipilimumab) are currently used for the treatment of advanced stage cancers and have demonstrated notable clinical efficacy [2].